OptiNose Inc. Stock News

OptiNose's Xhance is already approved in one indication with another set to read out pivotal data from two trials in late 2021 and early 2022. Xhance had $48.4 million in sales in the sinusitis patien

Co-founder and Chief Scientific Officer of Optinose AS honored for his invention of the technology used in the Optinose Exhalation Delivery System Co-founder and Chief Scientific Officer of Optinose A

YARDLEY, Pa., June 2, 2021 /PRNewswire/ -- Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allerg

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2021 Results - Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of 5.77% and 4.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

YARDLEY, Pa., April 27, 2021 /PRNewswire/ -- Optinose, (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced resu

YARDLEY, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced tha

OptiNose's (OPTN) CEO Peter Miller on Q4 2020 Results - Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of -2.22% and -10.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

The stock price of OptiNose Inc (NASDAQ: OPTN) is trading at over 10% pre-market. This is why it happened.

Shares of OptiNose (NASDAQ:OPTN) decreased 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 20.69% over the past year to ($0.46), which were

OptiNose (NASDAQ:OPTN) unveils its next round of earnings this Wednesday, March 03. Here is Benzinga's everything-that-matters guide for the earnings announcement.

OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conference Call and Webcast to be held March 3, 2021 at 8:00 a.m. Eastern Time

YARDLEY, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Opti N ose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announ